UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $1.11 Million in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 44,229 shares of the company's stock, valued at approximately $1,105,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.06% of Kiniksa Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at about $189,000. MetLife Investment Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 21,721 shares of the company's stock valued at $543,000 after purchasing an additional 12,239 shares during the last quarter. BNP Paribas Financial Markets raised its position in Kiniksa Pharmaceuticals by 121.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 192,926 shares of the company's stock worth $4,821,000 after purchasing an additional 105,924 shares during the period. FMR LLC boosted its position in Kiniksa Pharmaceuticals by 36,925.0% during the third quarter. FMR LLC now owns 696,810 shares of the company's stock valued at $17,413,000 after buying an additional 694,928 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at about $354,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Insider Activity at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total transaction of $456,790.00. Following the completion of the transaction, the chief operating officer now directly owns 109,975 shares in the company, valued at approximately $2,955,028.25. This trade represents a 13.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of the company's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the sale, the chief financial officer now owns 22,958 shares in the company, valued at $492,449.10. The trade was a 28.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 44,592 shares of company stock worth $1,110,364 over the last ninety days. 54.57% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on KNSA. Evercore ISI boosted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They set a "buy" rating and a $40.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and an average target price of $36.60.

Kiniksa Pharmaceuticals Stock Up 2.1 %

Shares of KNSA traded up $0.43 during mid-day trading on Thursday, hitting $20.49. 382,887 shares of the company's stock traded hands, compared to its average volume of 396,982. The business's 50-day moving average price is $23.01 and its 200-day moving average price is $23.11. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $16.56 and a 1 year high of $28.15. The firm has a market capitalization of $1.48 billion, a P/E ratio of -146.35 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $112.21 million during the quarter, compared to analysts' expectations of $111.51 million. During the same quarter last year, the business earned ($0.20) earnings per share. The business's quarterly revenue was up 67.4% on a year-over-year basis. Sell-side analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.